Come si colloca il rapporto ZYNE di PB rispetto ai suoi colleghi?

ZYNE ha un buon valore in base al suo rapporto Price-To-Book ( 2.3 x) rispetto alla media dei peer ( 16.4 x).

Come si colloca il ZYNE's PB Ratio rispetto ad altre aziende del US Pharmaceuticals settore?

ZYNE è costoso in base al suo rapporto Price-To-Book ( 2.3 x) rispetto alla media del settore US Pharmaceuticals ( 1.8 x).

Qual è il ZYNE PB Ratio rispetto al suo Fair PB Ratio? Si tratta del PB Ratio atteso, tenendo conto delle previsioni di crescita degli utili, dei margini di profitto e di altri fattori di rischio della società.

Dati insufficienti per calcolare il Fair Ratio di ZYNE Price-To-Book per l'analisi di valutazione.

Qual è il prezzo equo di ZYNE se si considerano i suoi flussi di cassa futuri? Per questa stima utilizziamo un modello di Discounted Cash Flow.

ZYNE ( $1.3 ) viene scambiato al di sotto della nostra stima del [[fair value]] ( $53.8 )

Qual è la previsione a 12 mesi degli analisti e abbiamo una qualche fiducia statistica nell'obiettivo di prezzo del consenso?

Il prezzo obiettivo è inferiore al prezzo attuale delle azioni.

Zynerba Pharmaceuticals (Nasdaq:ZYNE) - Prezzo delle azioni, notizie e analisi

ZYNE Panoramica delle azioni

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Maggiori dettagli

ZYNE analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 97.6% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 67.21% all'anno

Gli utili sono cresciuti del 0.8% all'anno negli ultimi 5 anni

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Ha meno di 1 anno di pista di cassa

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Non ha una capitalizzazione di mercato significativa ( $66M )

+ 2 più rischi

Zynerba Pharmaceuticals, Inc. Concorrenti

Landos Biopharma

NasdaqCM:LABP

US$71.7m

MariMed

OTCPK:MRMD

US$57.2m

Regencell Bioscience Holdings

NasdaqCM:RGC

US$82.2m

Nutriband

NasdaqCM:NTRB

US$53.3m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Zynerba Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.30
Massimo di 52 settimane	US$1.40
Minimo di 52 settimane	US$0.25
Beta	1.19
1Variazione di 1 mese	-1.52%
Variazione a 3 mesi	282.24%
Variazione di 1 anno	96.08%
3Variazione a 3 anni	-65.79%
Variazione a 5 anni	-82.17%
Variazione dall'IPO	-92.00%

Notizie e aggiornamenti recenti

Recent updates

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Mar 01

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 11

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Oct 06

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

Aug 10

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Jul 22

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Jul 21

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Mar 23

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Dec 02

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

May 27

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Dec 17

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Nov 23

Zynerba Pharmaceuticals EPS beats by $0.12

Nov 09

Zynerba Zygel Remains A Huge Part Of The Company's Pipeline Despite Setback

Oct 29

Rendimenti per gli azionisti

	ZYNE	US Pharmaceuticals	US Mercato
7D	4.0%	2.6%	0.5%
1Y	96.1%	13.1%	30.7%

Ritorno vs Industria: ZYNE ha superato il US Pharmaceuticals che ha restituito 13.1 % nell'ultimo anno.

Rendimento vs Mercato: ZYNE ha superato il mercato US che ha restituito 30.7 % nell'ultimo anno.

Volatilità dei prezzi

Is ZYNE's price volatile compared to industry and market?
ZYNE volatility
ZYNE Average Weekly Movement	84.2%
Pharmaceuticals Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di ZYNE è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di ZYNE è aumentata da 43% a 84% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2007	26	Armando Anido	www.zynerba.com

Zynerba Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Zynerba Pharmaceuticals con la sua capitalizzazione di mercato?
ZYNE statistiche fondamentali
Capitalizzazione di mercato	US$65.60m
Guadagni(TTM)	-US$37.58m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-1.7x

Rapporto P/E

ZYNE è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ZYNE Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$37.58m
Guadagni	-US$37.58m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.74
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato ZYNE nel lungo periodo?

Vedi performance storica e confronto

ZYNE Panoramica delle azioni

Premi

Analisi del rischio

Zynerba Pharmaceuticals, Inc. Concorrenti

NasdaqCM:LABP

US$71.7m

OTCPK:MRMD

US$57.2m

NasdaqCM:RGC

US$82.2m

NasdaqCM:NTRB

US$53.3m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

Price target decreased by 78% to US$1.26

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Price target increased by 7.9% to US$5.80

Forecast to breakeven in 2025

Price target increased by 30% to US$7.00

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$5.44

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Price target increased to US$8.33

Insufficient new directors

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba stock rises on US patent for cannabidiol Zygel's use for Fragile X syndrome

Zynerba Pharmaceuticals GAAP EPS of -$0.24 misses by $0.01

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba inks equity funding contract of up to $20M with Lincoln Park Capital

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Price target decreased to US$6.95

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Here's Why We're Watching Zynerba Pharmaceuticals' (NASDAQ:ZYNE) Cash Burn Situation

Price target decreased to US$6.95

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

We Think Zynerba Pharmaceuticals (NASDAQ:ZYNE) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

New 90-day high: US$5.08

New 90-day low: US$3.27

Zynerba Pharmaceuticals, Inc. Provides Regulatory Update on Zygel™ in Fragile X Syndrome

Zynerba Pharma shares slip 10% on Zygel update in Fragile X syndrome

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Invest In Growth?

New 90-day high: US$3.88

Zynerba Pharmaceuticals EPS beats by $0.12